Replimune (REPL) Research & Development (2017 - 2026)

Replimune (REPL) has 10 years of Research & Development data on file, last reported at $52.3 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 3.06% year-over-year to $52.3 million; the trailing twelve-month figure through Mar 2026 stood at $221.2 million (up 17.4% YoY), and the FY2026 full-year result was $221.2 million, up 16.75% from the prior year.
• Research & Development fell to $52.3 million in Q1 2026, from $53.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $57.9 million in Q3 2025 to a low of $21.7 million in Q1 2022.
• A 5-year average of $43.1 million and a median of $43.0 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 74.61% in 2023 and dropped 11.51% in 2024, its largest moves.
• Tracing REPL's Research & Development over 5 years: stood at $30.3 million in 2022, then surged by 41.59% to $42.8 million in 2023, then gained by 12.04% to $48.0 million in 2024, then climbed by 10.7% to $53.1 million in 2025, then retreated by 1.54% to $52.3 million in 2026.
• Business Quant data shows REPL's Research & Development at $52.3 million in Q1 2026, $53.1 million in Q4 2025, and $57.9 million in Q3 2025.